journal
MENU ▼
Read by QxMD icon Read
search

American Journal of Hematology

journal
https://www.readbyqxmd.com/read/28103640/addition-of-cladribine-to-the-standard-induction-treatment-improves-outcomes-in-a-subset-of-elderly-aml-patients-results-of-a-randomized-polish-adult-leukemia-group-palg-phase-ii-trial
#1
Agnieszka Pluta, Tadeusz Robak, Agata Wrzesien-Kus, Bozena Katarzyna Budziszewska, Kazimierz Sulek, Ewa Wawrzyniak, Magdalena Czemerska, Malgorzata Zwolinska, Aleksandra Golos, Aleksandra Holowiecka-Goral, Slawomira Kyrcz-Krzemien, Jaroslaw Piszcz, Janusz Kloczko, Monika Mordak-Domagala, Andrzej Lange, Małgorzata Razny, Krzysztof Madry, Wieslaw Wiktor-Jedrzejczak, Sebastian Grosicki, Aleksandra Butrym, Kazimierz Kuliczkowski, Krzysztof Warzocha, Jerzy Holowiecki, Sebastian Giebel, Richard Szydlo, Agnieszka Wierzbowska
Intensive induction chemotherapy using anthracycline and cytarabine backbone is considered the most effective upfront therapy in physically fit older patients with acute myeloid leukemia (AML). However, outcomes of the standard induction in elderly AML are inferior to those observed in younger patients and they are still unsatisfactory. As addition of cladribine to the standard induction therapy is known to improve outcome in younger AML patients, the present randomized phase II study compares efficacy and toxicity of the DAC (daunorubicin plus cytarabine plus cladribine) regimen with the standard DA (daunorubicin plus cytarabine) regimen in the newly diagnosed AML patients over 60 years of age...
January 19, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28103625/phase-ii-study-of-imatinib-based-chemotherapy-for-newly-diagnosed-bcr-abl-positive-acute-lymphoblastic-leukemia
#2
Shin Fujisawa, Shuichi Mizuta, Hideki Akiyama, Yasunori Ueda, Yasutaka Aoyama, Yoshihiro Hatta, Kazuhiko Kakihana, Nobuaki Dobashi, Isamu Sugiura, Yasushi Onishi, Tomoya Maeda, Kiyotoshi Imai, Shigeki Ohtake, Yasushi Miyazaki, Kazunori Ohnishi, Keitaro Matsuo, Tomoki Naoe
This study investigated the efficacy of imatinib based therapy with intensified consolidation therapy in patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) to prevent early relapse. We conducted a phase II trial of imatinib-combined chemotherapy for newly diagnosed BCR-ABL-positive ALL in adults. Sixty-eight patients were included in the trial between October 2008 and December 2010. The median age was 49 years, with 28 patients >55 years of age. Sixty-five patients achieved CR (95...
January 19, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28093802/simple-matters-in-complex-times
#3
Aliyah R Sohani
No abstract text is available yet for this article.
January 17, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28076892/impact-of-achievement-of-complete-cytogenetic-response-on-outcome-in-patients-with-myelodysplastic-syndromes-treated-with-hypomethylating-agents
#4
Elias Jabbour, Paolo Strati, Monica Cabrero, Susan O'Brien, Farhad Ravandi, Carlos Bueso-Ramos, Qiao Wei, Jianhua Hu, Simon Abi Aad, Nicholas J Short, Courtney Dinardo, Naval Daver, Tapan Kadia, William Wierda, Yue Wei, Simona Colla, Gautam Borthakur, Jorge Cortes, Zeev Estrov, Hagop Kantarjian, Guillermo Garcia-Manero
We reviewed 216 consecutive patients with MDS and abnormal karyotype treated with hypomethylating agents between 4/04 and 10/12. Median follow-up was 17 months. Using IWG criteria, best responses were complete response (CR) in 79 patients (37%), partial response (PR) in 4 (2%), and hematologic improvement (HI) in 10 (5%). Cytogenetic response (CyR) was achieved in 78 patients (36%): complete (CCyR) in 62 (29%) and partial in 16 (7%). CyR was achieved in 48 of 79 patients (61%) with CR, 1 of 14 (7%) with PR/HI, and in 29 of the 123 (24%) with no morphologic response...
January 11, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28076884/impact-of-fludarabine-based-induction-therapy-on-outcome-of-flt3-npm1-cytogenetically-normal-acute-myeloid-leukemia
#5
LETTER
Mario Tiribelli, Antonella Geromin, Daniela Damiani
No abstract text is available yet for this article.
January 11, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28066934/acute-pain-in-adolescents-and-young-adults-with-sickle-cell-disease-delayed-and-increased-opioid-dosing-following-transition-to-adult-care
#6
LETTER
Nathan Stehouwer, Preston Edge, Bohyung Katie Park, Connie Piccone, Jane Little
No abstract text is available yet for this article.
January 9, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28066929/diagnostic-work-up-of-acute-myeloid-leukemia
#7
Olga K Weinberg, Aliyah R Sohani, Parul Bhargava, Valentina Nardi
Acute myeloid leukemia (AML) is characterized by a clonal expansion of undifferentiated myeloid precursors resulting in impaired hematopoiesis and bone marrow failure. In 2016, the World Health Organization (WHO) published revisions to the classification of myeloid neoplasms and acute leukemias. Similar to the 2008 classification, the updated classification incorporates clinical features, morphology, immunophenotyping, and cytogenetics, with greater emphasis on molecular genetics, to define disease entities...
January 9, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28066926/low-affinity-haemoglobinopathy-hb-vigo-due-to-a-new-mutation-of-beta-globin-gene-c200-a-t-lys-ile-a-cause-of-rare-anaemia-misdiagnosis
#8
LETTER
María Del Mar Mañú Pereira, Paloma Ropero, Carmen Loureiro, Joan Lluis Vives Corrons
No abstract text is available yet for this article.
January 9, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28066925/association-of-immune-globulin-intravenous-igiv-and-thromboembolic-adverse-events-tees
#9
LETTER
Mikhail V Ovanesov, Mikhail D Menis, Dorothy E Scott, Richard Forshee, Steven Anderson, Wilson Bryan, Basil Golding
No abstract text is available yet for this article.
January 9, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28066923/reply-to-ruan-x-et-al-a-comment-on-pattern-of-opioid-use-in-sickle-cell-disease
#10
LETTER
Jin Han, Santosh L Saraf, Roberto F Machado, Victor R Gordeuk
No abstract text is available yet for this article.
January 9, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28066921/a-reply-to-ovanesov-et-al
#11
LETTER
Eric M Ammann, Elizabeth A Chrischilles
No abstract text is available yet for this article.
January 9, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28054397/conventional-cytogenetics-for-myeloid-neoplasms-in-the-era-of-next-generation-sequencing
#12
Frank C Kuo, David P Steensma, Paola Dal Cin
In this issue of the American Journal of Hematology, Weinberg et al.(1) discuss how multiple diagnostic techniques should be integrated in the diagnosis of acute myeloid leukemia (AML) and the risk stratification of patients.Ever since the discovery of Philadelphia chromosome more than 50 years ago(2) , conventional cytogenetic assays, including karyotype and fluorescent in situ hybridization (FISH), have played a critical role in classification, diagnosis and management of AML and other myeloid neoplasms. Most, if not all, of the recurrent chromosomal rearrangements commonly seen in AML are now well-described and the genes involved in these rearrangements have been identified...
January 5, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28052520/ikaros-expression-in-distinct-bone-marrow-cell-populations-as-a-candidate-biomarker-for-outcome-with-lenalidomide-dexamethasone-therapy-in-multiple-myeloma
#13
Arnold Bolomsky, Wolfgang Hübl, Stefano Spada, Ercan Müldür, Karin Schlangen, Daniel Heintel, Alberto Rocci, Adalbert Weißmann, Veronique Fritz, Martin Willheim, Niklas Zojer, Antonio Palumbo, Heinz Ludwig
Immunomodulatory drugs (IMiDs) are a cornerstone in the treatment of multiple myeloma (MM), but specific markers to predict outcome are still missing. Recent work pointed to a prognostic role for IMiD target genes (e.g. CRBN). Moreover, indirect activity of IMiDs on immune cells correlated with outcome, raising the possibility that cell populations in the bone marrow (BM) microenvironment could serve as biomarkers. We therefore analysed gene expression levels of six IMiD target genes in whole BM samples of 44 myeloma patients treated with lenalidomide-dexamethasone...
January 4, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28052478/sepsis-and-persisting-neutropenia-in-a-drug-addict
#14
Roman M Shapiro, Michelle P Zeller, Theodore E Warkentin
No abstract text is available yet for this article.
January 4, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28052467/the-combination-of-cyclosporine-and-mycophenolate-mofetil-is-less-effective-than-cyclosporine-and-methotrexate-in-the-prevention-of-acute-graft-versus-host-disease-after-stem-cell-transplantation-from-unrelated-donors
#15
Ronit Yerushalmi, Noga Shem-Tov, Ivetta Danylesko, Roni Shouval, Arnon Nagler, Avichai Shimoni
Acute graft-versus-host disease (GVHD) is the major treatment-related complication after stem-cell transplantation (SCT) from unrelated-donors. Several GVHD prophylaxis regimens have been explored, but no regimen has shown superiority. We analyzed transplantation outcomes in 472 consecutive unrelated-donor SCT recipients, using cyclosporine/methotrexate (MTX, n=314) or cyclosporine/mycophenolate-mofetil (MMF, n=158) for GVHD prophylaxis. Neutrophil engraftment was faster after MMF, day 11 and 14, respectively (P=0...
January 4, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28052422/can-we-have-some-platelets-please-a-reason-not-to-put-your-microscope-on-ebay
#16
Wenchee Siow, Barbara J Bain
No abstract text is available yet for this article.
January 4, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28052413/a-randomized-trial-of-iron-isomaltoside-versus-iron-sucrose-in-patients-with-iron-deficiency-anemia
#17
Richard Derman, Eloy Roman, Manuel R Modiano, Maureen M Okam, Lars L Thomsen, Michael Auerbach
Iron deficiency anemia (IDA) is common in many chronic diseases and intravenous (IV) iron offers a rapid and efficient iron correction. This trial compared the efficacy and safety of iron isomaltoside and iron sucrose in patients with IDA who were intolerant of, or unresponsive to, oral iron. The trial was an open-label, comparative, multi-center trial. 511 patients with IDA from different causes were randomized 2:1 to iron isomaltoside or iron sucrose and followed for 5 weeks. The cumulative dose of iron isomaltoside was based on body weight and hemoglobin (Hb), administered as either a 1000 mg infusion over more than 15 minutes or 500 mg injection over 2 minutes...
January 4, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28052408/relapse-risk-and-survival-in-patients-with-flt3-acute-myeloid-leukemia-undergoing-stem-cell-transplantation
#18
Sameh Gaballa, Rima Saliba, Betul Oran, Jonathan E Brammer, Julianne Chen, Gabriela Rondon, Amin M Alousi, Partow Kebriaei, David Marin, Uday R Popat, Borje S Andersson, Elizabeth J Shpall, Elias Jabbour, Naval Daver, Michael Andreeff, Farhad Ravandi, Jorge Cortes, Keyur Patel, Richard E Champlin, Stefan O Ciurea
In patients with AML with FMS-like tyrosine kinase 3 (FLT3) mutations, the significance of minimal residual disease (MRD) detected by PCR before allogeneic stem cell transplantation (SCT) on outcomes after transplant remains unclear. We identified 200 patients with FLT3-AML who underwent SCT at our institution. Disease status at transplant was: first or second complete remission (CR1/CR2, n=119), high-risk CR (third or subsequent CR, marrow hypoplasia, or incomplete count recovery) (CR-HR, n=31), and morphological evidence of active disease (AD, n=50)...
January 4, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28052380/a-comment-on-pattern-of-opioid-use-in-sickle-cell-disease
#19
LETTER
Xiulu Ruan, Hong Wu, Dian Wang
No abstract text is available yet for this article.
January 4, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28052375/unexplained-isolated-hyperferritinemia-without-iron-overload
#20
Giulia Ravasi, Sara Pelucchi, Raffaella Mariani, Marco Casati, Federico Greni, Cristina Arosio, Irene Pelloni, Silvia Majore, Paolo Santambrogio, Sonia Levi, Alberto Piperno
Although hyperferritinemia may be reflective of elevated total body iron stores, there are conditions in which ferritin levels are disproportionately elevated relative to iron status. Autosomal dominant forms of hyperferritinemia due to mutations in the L-ferritin IRE or in A helix of L-ferritin gene have been described, however cases of isolated hyperferritinemia still remain unsolved. We describe 12 Italian subjects with unexplained isolated hyperferritinemia (UIH). Four probands have affected siblings, but no affected parents or offspring...
January 4, 2017: American Journal of Hematology
journal
journal
26814
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"